B. Peraux

A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients.

L. Annemans, M. Nechelput, H. Warie, 2004, Acta gastro-enterologica Belgica.

A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels.

L. Annemans, Y. Horsmans, C. Beguin, 2007, Acta gastro-enterologica Belgica.

A health economic model to assess the cost‐effectiveness of PEG IFN α‐2a and ribavirin in patients with mild chronic hepatitis C

M. Mouchart, L. Annemans, Y. Horsmans, 2007, Journal of viral hepatitis.

A health economic model to assess the cost‐effectiveness of PEG IFN α‐2a and ribavirin in patients with mild chronic hepatitis C

M. Mouchart, L. Annemans, Y. Horsmans, 2007, Journal of viral hepatitis.